A Phase 2 Open-Label, Multicenter, Dose Optimization Clinical Study of the Safety, Tolerability, and Pharmacokinetic (PK) and Pharmacodynamic (PD) Profiles of Cfi-400945 As a Single Agent or in Combination with Azacitidine or Decitabine in Patients with Acute Myeloid Leukemia

Brian A Jonas,Dale L Bixby,Joseph M Brandwein,Karen W.L Yee,Tracy Murphy,Mark D Minden,Glenn C Michelson,Mark R Bray,Emily Elizabeth Roberts-Thomson,Gautam Borthakur

doi:10.1182/blood-2020-136004

A Phase 2 Open-Label, Multicenter, Dose Optimization Clinical Study of the Safety, Tolerability, and Pharmacokinetic (PK) and Pharmacodynamic (PD) Profiles of Cfi-400945 As a Single Agent or in Combination with Azacitidine or Decitabine in Patients with Acute Myeloid Leukemia

Brian A Jonas, Dale L Bixby + Show 8 more

Open Access

https://doi.org/10.1182/blood-2020-136004

Copy DOI

Journal: Blood	Publication Date: Nov 5, 2020
Citations: 1

Affiliation: University of Alberta, Princess Margaret Cancer Centre, University Health Network, University of Michigan–Ann Arbor, University of California, Davis, The University of Texas MD Anderson Cancer Center

#Research Funding #Polo-like Kinase 4 + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

A Phase 2 Open-Label, Multicenter, Dose Optimization Clinical Study of the Safety, Tolerability, and Pharmacokinetic (PK) and Pharmacodynamic (PD) Profiles of Cfi-400945 As a Single Agent or in Combination with Azacitidine or Decitabine in Patients with Acute Myeloid Leukemia

Full Text